Provided by Tiger Trade Technology Pte. Ltd.

Medicus Pharma Ltd.

0.1521
-0.0072-4.52%
Post-market: 0.1507-0.0014-0.92%16:34 EDT
Volume:3.08M
Turnover:466.31K
Market Cap:9.61M
PE:-0.09
High:0.1556
Open:0.1510
Low:0.1475
Close:0.1593
52wk High:3.05
52wk Low:0.1440
Shares:63.18M
Float Shares:46.69M
Volume Ratio:0.28
T/O Rate:6.60%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6597
EPS(LYR):-2.7356
ROE:-7446.11%
ROA:-110.67%
PB:-5.45
PE(LYR):-0.06

Loading ...

Medicus Pharma - Terminates Standby Equity Purchase Agreement with Yorkville Effective Sept 11, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 14

Medicus Pharma Announces Equity-Based Bonus Share Issuance

TIPRANKS
·
Sep 11

Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Labcorp Holdings (LH)

TIPRANKS
·
Sep 11

Medicus Pharma Issues 8,529,412 Restricted Shares in Lieu of $1.45 Million Cash Bonuses

Reuters
·
Sep 11

Medicus Selects 200 Μg SkinJect Patch as Lead Dose in Final Phase 2 Skin Cancer Study Report

Reuters
·
Sep 10

Medicus Pharma Publishes Abridged Final Phase 2 Skinject® Clinical Study Report (CSR) Results Identifying 200 ΜG D-Mna Patch as the Lead Development Dose

THOMSON REUTERS
·
Sep 10

Analysts Are Bullish on These Healthcare Stocks: IDEAYA Biosciences (IDYA), Medicus Pharma Ltd (MDCX)

TIPRANKS
·
Sep 09

Medicus Pharma Sharpened Strategy Centers on Precision Oncology and Targeted Rare Disease Programs

TIPRANKS
·
Sep 08

Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company

THOMSON REUTERS
·
Sep 08

Medicus Pharma - Cd228v Established as Principal Strategic Priority for Medicus Pharma

THOMSON REUTERS
·
Sep 08

Medicus Pharma Pivots to Precision Oncology, Prioritizing Cd228v Melanoma Proof-of-Concept Study

Reuters
·
Sep 08

U.S. Stocks on the MOVE-Gold Miners, Polestar Automotive, Nvidia

Reuters
·
Sep 03

Medicus Pharma Shares Down 20.5% Premarket; Co, Pfizer Enter Licensing Deal for Experimental Cancer Therapy

THOMSON REUTERS
·
Sep 03

Medicus Pharma Secures Global Pfizer License for CD228V

TIPRANKS
·
Sep 03

Medicus Pharma Surges on Pfizer Licensing Deal for Experimental Cancer Therapy

Reuters
·
Sep 03

Medicus Pharma Signs Co-Development, Licensing Deal with Pfizer for Cd228v Antibody-Drug Conjugate

Reuters
·
Sep 03

Medicus Pharma - Pays Pfizer $12 Mln Upfront, $15 Mln Due on First Anniversary - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Pfizer Paid the Company a One-Time, Non-Refundable Payment of $2.0 Million

THOMSON REUTERS
·
Sep 03

Medicus Pharma - Enters Co-Development and License Agreement with Pfizer on Sept 2, 2026 - SEC Filing

THOMSON REUTERS
·
Sep 03

Medicus Pharma Advances SkinJect and Teverelix Amid Financing Gains and Going-Concern Risk

TIPRANKS
·
Aug 13